Session » Fibromyalgia and Soft Tissue Disorders II

Meeting: 2012 ACR/ARHP Annual Meeting

Abstract Number: 2641

Time-to-Improvement of Pain and Sleep in Clinical Trials of Pregabalin Treatment of Fibromyalgia

Abstract Number: 2642

Rate and Predictors of Work Disability in Fibromyalgia

Abstract Number: 2643

Grey Matter Decrease in Fibromyalgia Is Related to Pain Catastrophizing and Pain Sensitivity

Abstract Number: 2644

Functional Magnetic Resonance Imaging of Working Memory in Fibromyalgia: Support for a “Competing Demands” Theory of Cognitive Function in Chronic Pain

Abstract Number: 2645

The Transcription Factor Mohawk Plays an Important Role for Maintaining Human Anterior Cruciate Ligament Homeostasis

Abstract Number: 2646

Cost-Effectiveness of Tai Chi Mind-Body Exercise for the Treatment of Fibromyalgia

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.